DNA repair pathways in breast cancer: from mechanisms to clinical applications

被引:11
作者
Tufail, Muhammad [1 ]
机构
[1] Shanxi Univ, Inst Biomed Sci, Taiyuan 030006, Peoples R China
关键词
Breast cancer; DNA repair pathways; Drug resistance; Therapeutic approaches; Clinical applications; BASE-EXCISION-REPAIR; FANCONI-ANEMIA PATHWAY; CELL-CYCLE KINETICS; END-JOINING GENES; HOMOLOGOUS RECOMBINATION; PARP INHIBITORS; MONOCLONAL-ANTIBODIES; PROSTATE-CANCER; LUNG-CANCER; RISK;
D O I
10.1007/s10549-023-06995-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundBreast cancer (BC) is a complex disease with various subtypes and genetic alterations that impact DNA repair pathways. Understanding these pathways is essential for developing effective treatments and improving patient outcomes.Area coveredThis study investigates the significance of DNA repair pathways in breast cancer, specifically focusing on various pathways such as nucleotide excision repair, base excision repair, mismatch repair, homologous recombination repair, non-homologous end joining, fanconi anemia pathway, translesion synthesis, direct repair, and DNA damage tolerance. The study also examines the role of these pathways in breast cancer resistance and explores their potential as targets for cancer treatment.ConclusionRecent advances in targeted therapies have shown promise in exploiting DNA repair pathways for BC treatment. However, much research is needed to improve the efficacy of these therapies and identify new targets. Additionally, personalized treatments that target specific DNA repair pathways based on tumor subtype or genetic profile are being developed. Advances in genomics and imaging technologies can potentially improve patient stratification and identify biomarkers of treatment response. However, many challenges remain, including toxicity, resistance, and the need for more personalized treatments. Continued research and development in this field could significantly improve BC treatment.
引用
收藏
页码:305 / 321
页数:17
相关论文
共 185 条
[1]  
Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.0.CO
[2]  
2-L
[3]   A rare FANCA gene variation as a breast cancer susceptibility allele in an Iranian population [J].
Abbasi, Sakineh ;
Rasouli, Mina .
MOLECULAR MEDICINE REPORTS, 2017, 15 (06) :3983-3988
[4]   Multifaceted activities of DNA polymerase : beyond translesion DNA synthesis [J].
Acharya, Narottam ;
Manohar, Kodavati ;
Peroumal, Doureradjou ;
Khandagale, Prashant ;
Patel, Shraddheya Kumar ;
Sahu, Satya Ranjan ;
Kumari, Premlata .
CURRENT GENETICS, 2019, 65 (03) :649-656
[5]   Roles of trans-lesion synthesis (TLS) DNA polymerases in tumorigenesis and cancer therapy [J].
Anand, Jay ;
Chiou, Lilly ;
Sciandra, Carly ;
Zhang, Xingyuan ;
Hong, Jiyong ;
Wu, Di ;
Zhou, Pei ;
Vaziri, Cyrus .
NAR CANCER, 2023, 5 (01)
[6]   PARP Inhibitor Treatment in Ovarian and Breast Cancer [J].
不详 .
CURRENT PROBLEMS IN CANCER, 2011, 35 (01) :7-50
[7]   When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials [J].
Antonarakis, Emmanuel S. ;
Gomella, Leonard G. ;
Petrylak, Daniel P. .
EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05) :594-611
[8]   FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer [J].
Arceci, Anthony ;
Bonacci, Thomas ;
Wang, Xianxi ;
Stewart, Kyle ;
Damrauer, Jeffrey S. ;
Hoadley, Katherine A. ;
Emanuele, Michael J. .
CELL REPORTS, 2019, 26 (11) :3076-+
[9]   The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells [J].
Arun, Banu ;
Akar, Ugur ;
Gutierrez-Barrera, Angelica M. ;
Hortobagyi, Gabriel N. ;
Ozpolat, Bulent .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (01) :262-268
[10]  
Aykan K., 2022, Demiroglu Bilim Universitesi Florence Nightingale Tip Dergisi, V8, P130